ABCL on Nasdaq
AbCellera Biologics Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with CytomX Therapeutics, Inc., OMEROS CORP or Bicycle Therapeutics (United Kingdom), or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-289.0%Operating margin3
-194.9%Net margin3
160.6%Revenue growth, 20253
-15.1%Return on equity3
-$174.1MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License brought in 62% of the revenue AbCellera Biologics Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| License | $969.0K | $1.0M | $46.9M |
| Research Fees | $35.6M | $26.3M | $27.2M |
| Milestone Payments | $1.5M | $1.5M | $1.0M |
Regions
Canada brought in 85% of the revenue AbCellera Biologics Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Canada | $36.0M | $26.2M | $64.0M |
| United States | $2.0M | $2.7M | $11.1M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development86¢$186.8M
- Income tax14¢$31.2M
Out of $75.1M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $75.1M | $28.8M | $38.0M |
| Research and development | $186.8M | $167.3M | $175.7M |
| Sales, general and administrative | $83.2M | $85.5M | $75.2M |
| Depreciation, amortization, and impairment | $22.2M | $90.8M | $24.4M |
| Total operating expenses | $292.2M | $343.6M | $275.2M |
| Loss from operations | -$217.1M | -$314.8M | -$237.2M |
| Interest income | -$28.3M | -$38.5M | -$42.2M |
| Grants and incentives | -$13.9M | -$13.6M | -$14.2M |
| Other (Note 15) | $2.7M | -$62.3M | -$6.8M |
| Total other income | -$39.5M | -$114.4M | -$63.2M |
| Loss before income tax | -$177.6M | -$200.4M | -$174.0M |
| Income tax recovery | -$31.2M | -$37.5M | -$27.6M |
| Net loss | -$146.4M | -$162.9M | -$146.4M |
| Foreign currency translation adjustment | $144.0K | -$2.7M | -$329.0K |
| Comprehensive loss | -$146.3M | -$165.5M | -$146.7M |
| Basic (in dollars per share) | -$0.49 | -$0.55 | -$0.51 |
| Diluted (in dollars per share) | -$0.49 | -$0.55 | -$0.51 |
| Basic (in shares) | 298.7M shares | 294.3M shares | 289.2M shares |
| Diluted (in shares) | 298.7M shares | 294.3M shares | 289.2M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | 61.8M CAD | 55.6M CAD | |
| Marketable securities | $405.3M | $469.3M | |
| Total cash, cash equivalents, and marketable securities | $533.8M | $625.6M | |
| Accounts and accrued receivable | $58.3M | $33.6M | |
| Restricted cash | $25.0M | $25.0M | |
| Other current assets | $111.1M | $67.1M | |
| Total current assets | $728.2M | $751.4M | |
| Property and equipment, net | $428.0M | $340.4M | |
| Intangible assets, net | $38.4M | $42.1M | |
| Goodwill | $47.8M | $47.8M | |
| Investments in equity accounted investees | $62.6M | $82.3M | |
| Other long-term assets | $51.9M | $96.5M | |
| Total long-term assets | $628.7M | $609.2M | |
| Total assets | $1.4B | $1.4B | |
| Accounts payable and other current liabilities | $50.8M | $55.0M | |
| Contingent consideration payable | $0 | $8.1M | |
| Deferred revenue | $13.5M | $13.5M | |
| Total current liabilities | $64.3M | $76.6M | |
| Operating lease liability | $137.4M | $60.7M | |
| Deferred government contributions | $174.5M | $149.9M | |
| Deferred tax liability | $9.1M | $10.1M | |
| Other long-term liabilities | $4.8M | $7.2M | |
| Total long-term liabilities | $325.7M | $227.9M | |
| Total liabilities | $390.0M | $304.5M | |
| Common shares: no par value, unlimited authorized shares at December 31, 2024 and December 31, 2025: 295,757,002 and 300,600,710 shares issued and outstanding at December 31, 2024 and December 31, 2025, respectively | $802.3M | $777.2M | |
| Additional paid-in capital | $198.3M | $166.4M | |
| Accumulated other comprehensive loss | -$4.2M | -$4.4M | |
| Accumulated earnings (deficit) | -$29.5M | $116.9M | |
| Total shareholders' equity | $966.9M | $1.1B | $1.2B |
| Total liabilities and shareholders' equity | $1.4B | $1.4B | |
| Common stock, no par value (in USD per share) | $0 | $0 | |
| Common stock, shares issued (in shares) | 300.6M shares | 295.8M shares | |
| Common stock, shares outstanding (in shares) | 300.6M shares | 295.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$146.4M | -$162.9M | -$146.4M |
| Depreciation of property and equipment | $18.4M | $12.5M | $12.8M |
| Amortization and impairment of intangible assets | $3.7M | $78.3M | $11.6M |
| Amortization of operating lease right-of-use assets | $6.7M | $6.1M | $6.5M |
| Stock-based compensation | $55.8M | $67.6M | $64.2M |
| Fair value (gain) loss on contingent consideration and investments | $4.5M | -$64.7M | -$8.0M |
| Other | -$3.3M | -$19.7M | $2.2M |
| Research fees and grants receivable | -$55.6M | -$75.1M | -$45.9M |
| Income taxes (payable) receivable | -$29.8M | $6.7M | $30.5M |
| Accounts payable and accrued liabilities | $3.5M | $10.6M | -$15.1M |
| Deferred revenue | -$2.2M | -$7.9M | -$14.0M |
| Deferred grant income | -$3.6M | $34.0M | $39.5M |
| Other assets | $17.1M | $6.0M | $18.3M |
| Net cash used in operating activities | -$131.3M | -$108.6M | -$43.9M |
| Purchases of property and equipment | -$42.8M | -$78.4M | -$76.9M |
| Purchase of marketable securities | -$436.0M | -$765.1M | -$1.0B |
| Proceeds from marketable securities | $506.1M | $937.9M | $910.9M |
| Receipt of grant funding | $21.3M | $35.7M | $25.3M |
| Distribution from equity accounted investees | $30.1M | $0 | $0 |
| Investment in and loans to equity accounted investees | -$7.1M | -$19.6M | -$13.7M |
| Proceeds from repayment of loan from joint venture partner | $33.3M | $0 | $0 |
| Long-term investments and other assets | -$17.1M | $10.9M | -$45.2M |
| Net cash provided by (used in) investing activities | $87.8M | $121.4M | -$221.1M |
| Payment of liability for in-licensing agreement and other | -$15.6M | -$729.0K | -$1.2M |
| Proceeds from long-term liabilities and other | $29.7M | $13.5M | $11.6M |
| Net cash provided by financing activities | $14.1M | $12.8M | $10.4M |
| Effect of exchange rate changes on cash and cash equivalents | $1.1M | -$2.6M | $589.0K |
| Increase (decrease) in cash and cash equivalents | -$28.4M | $23.0M | -$254.0M |
| Property and equipment in accounts payable | $2.0M | $12.8M | $13.6M |
| Right-of-use assets obtained in exchange for operating lease obligation | $76.1M | $1.9M | $1.2M |
Recent filings
- Aug 24, 20264
- Aug 18, 20264
- Aug 14, 20264
- Aug 14, 20264
- Aug 13, 20264
- Aug 13, 2026424B5
- Aug 13, 20268-K
- Aug 11, 2026424B5
- Aug 10, 20268-K
- Aug 7, 20268-K
- Aug 5, 20268-K
- Aug 5, 202610-Q
- Jul 29, 20268-K
- Jul 6, 20268-K
- Jul 6, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9